Brief: Allena Pharmaceuticals Reports Qtrly Loss Per Share $0.24

Allena Pharmaceuticals

09/03/2021 12:26

March 9 (Reuters) - Allena Pharmaceuticals Inc  ALNA.O :
    * ALLENA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL
YEAR 2020
FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
    * ALLENA PHARMACEUTICALS INC - RELOXALIASE CONTINUES TO
PROGRESS
THROUGH ONGOING PIVOTAL PHASE 3 URIROX-2 TRIAL FOR ENTERIC
HYPEROXALURIA
    * ALLENA PHARMACEUTICALS INC - ALLN-346 POISED TO ENTER
PHASE 1
MULTIPLE-ASCENDING DOSE AND PHASE 2A TRIALS FOR HYPERURICEMIA
AND GOUT
    * ALLENA PHARMACEUTICALS INC - NOW EXPECT TO COMPLETE
INTERIM
ANALYSIS IN OUR URIROX-2 TRIAL DURING SECOND OR Q3 OF 2022
    * ALLENA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.24

Source text for Eikon:  ID:nGNX1yHZWq 
Further company coverage:  ALNA.O 

 ((Reuters.Briefs@thomsonreuters.com;))